BioSpace News Archive

OncoNano Medicine, Inc. announced results from a Phase 2 study of its lead clinical development candidate, pegsitacianine

Antibe Therapeutics Inc. is pleased to provide an update following a full scientific and strategic review involving external experts and key opinion leaders.

Kojin Therapeutics Announces Luba Greenwood as Chief Executive Officer

Applied UV announced it has closed on the acquisition by its wholly-owned subsidiary, SteriLumen, Inc.

Mindset Pharma Inc. today announced that, under its Co-operative Psychedelics Evaluation Platform (“COPE”) program with InterVivo Solutions (“InterVivo”), the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across LSD, psilocybin, and 5-MeO-DMT.

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2021 financial results on Thursday, October 28, 2021.

Navidea Biopharmaceuticals, Inc. today announced the appointment of Thomas Forest Farb-Horch and Agnieszka Winkler to its Board of Directors, effective October 7, 2021

Trial is designed to advance pelareorep’s clinical development in China , the world’s second-largest pharmaceutical market

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application No. 17/381,005.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for third quarter ended September 30, 2021.